Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Area of Science:

• Oncology
• Urology
• Medical Research

Background:

• Traditional management for non-metastatic castration-resistant prostate cancer (nmCRPC) involved monitoring until disease progression.
• Delaying metastasis and symptom development in nmCRPC is a critical clinical challenge.
• Androgen deprivation therapy (ADT) is a standard treatment, but its limitations in nmCRPC necessitate novel approaches.

Purpose of the Study:

• To review recent advancements in managing non-metastatic castration-resistant prostate cancer (nmCRPC).
• To highlight the efficacy of next-generation androgen receptor (AR) axis inhibitors in this patient population.
• To assess the impact of these inhibitors on key clinical endpoints.

Main Methods:

• Review of clinical trials investigating next-generation AR axis inhibitors (apalutamide, darolutamide, enzalutamide) in nmCRPC.
• Analysis of data focusing on metastases-free survival and overall survival.
• Evaluation of other clinically meaningful endpoints related to disease progression and patient-reported outcomes.

Main Results:

• Next-generation AR inhibitors demonstrated a favorable impact on metastases-free survival in nmCRPC patients.
• These agents also showed significant improvements in overall survival compared to placebo or older treatments.
• Clinically meaningful endpoints, including time to symptomatic progression, were positively affected by these novel therapies.

Conclusions:

• Next-generation AR inhibitors represent a significant advancement in the treatment of nmCRPC.
• These drugs effectively delay the development of metastases and improve survival outcomes.
• The findings support the use of apalutamide, darolutamide, and enzalutamide in the management of nmCRPC.